Kalaris Therapeutics, Inc. (KLRS)
Biological Products, (No Diagnostic Substances)
Latest Price
$3.20
TTM P/E
--
Normalized P/E
--
Div Yield
--
Book Value
2.43
P/B Ratio
1.32
Institutional Ownership
75.7% held by institutions| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| SAMSARA BIOCAPITAL, LLC | 12.88M | $52.0M | 54.11% | -66.9K | 2026-06-30 |
| RTW INVESTMENTS, LP | 1.30M | $5.0M | 5.46% | -- | 2026-06-30 |
| Alyeska Investment Group, L.P. | 572.7K | $2.0M | 2.41% | -- | 2026-06-30 |
| Siren, L.L.C. | 435.8K | $1.0M | 1.83% | -- | 2026-06-30 |
| VANGUARD CAPITAL MANAGEMENT LLC | 398.7K | $1.0M | 1.67% | +143.4K | 2026-06-30 |
| Ikarian Capital, LLC | 360.0K | $1.0M | 1.51% | -- | 2026-06-30 |
| UBS Group AG | 262.1K | $1.0M | 1.10% | +255.9K | 2026-06-30 |
| RENAISSANCE TECHNOLOGIES LLC | 149.4K | -- | 0.63% | +83.2K | 2026-06-30 |
| MARSHALL WACE, LLP | 139.2K | -- | 0.58% | +71.3K | 2026-06-30 |
| GEODE CAPITAL MANAGEMENT, LLC | 114.0K | -- | 0.48% | +26.5K | 2026-06-30 |